Business Context and Reporting Period
Company: Predictive Oncology Inc. (POAI)
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Overview: The Company operates as a single segment focused on AI-driven oncology drug discovery. In Q3 2025, the Company adopted a "Treasury Strategy" to hold Aethir (ATH) tokens as a strategic compute reserve. The Company also completed a 1-for-15 reverse stock split effective September 30, 2025, to regain compliance with Nasdaq listing standards. Former operating segments (Birmingham and Eagan) are reported as discontinued operations.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $3,618 | $3,907 | $116,610 | $76,020 |
| Net Loss (Continuing Ops) | $(77,646,737) | $(2,129,880) | $(81,911,048) | $(8,150,654) |
| Net Loss (Total) | $(77,651,843) | $(3,094,690) | $(82,165,178) | $(10,494,794) |
| Loss Per Share (Basic/Diluted) | $(107.25) | $(7.26) | $(136.12) | $(31.20) |
| Cash and Equivalents (End of Period) | $181,667 | $2,959,733 | $181,667 | $2,959,733 |
| Total Assets | $3,137,298 | $4,972,517 | $3,137,298 | $4,972,517 |
| Total Liabilities | $80,565,220 | $5,175,127 | $80,565,220 | $5,175,127 |
| Stockholders' Deficit | $(77,427,922) | $(202,610) | $(77,427,922) | $(202,610) |
Note: The Q3 2025 Net Loss is heavily impacted by a non-cash loss on derivative instruments of $74,366,000 related to the valuation of warrants issued in a cryptocurrency private placement.
Material Changes vs. Prior Period
- Derivative Liability: A derivative liability of $74,366,000 was recorded in Q3 2025 due to the fair value adjustment of warrants issued in the "Crypto PIPE" offering. This resulted in a massive non-cash loss on the income statement, contrasting with negligible derivative activity in 2024.
- Operating Expenses: General and Administrative (G&A) expenses increased significantly in Q3 2025 ($2.6M vs $1.5M in Q3 2024), driven by legal fees related to the Renovaro lawsuit and increased stock-based compensation from RSU grants.
- Discontinued Operations: The Company disposed of its Eagan operating segment in March 2025 for $625,000. Results from the Birmingham and Eagan segments are now classified as discontinued operations.
- Capital Structure: The Company executed a 1-for-15 reverse stock split in September 2025. Common shares outstanding increased from 444,475 (Dec 2024) to 767,058 (Sep 2025) due to various equity issuances (ATM, private placements, warrant exercises) prior to the split adjustment.
Guidance, Outlook, Risks, and Unusual Items
- Treasury Strategy: The Company has pivoted to a digital asset treasury strategy focused on Aethir (ATH) tokens. As of November 10, 2025, the Company held approximately 5.70 billion ATH tokens valued at ~$152.8 million. Management intends to use proceeds from recent financings to acquire more ATH and earn yield through staking.
- Recent Financing (Subsequent Event): On October 7, 2025, the Company closed two private placements (Cash PIPE and Crypto PIPE) raising approximately $50.8 million in cash and receiving ATH tokens with a notional value of $292.7 million. Management believes this provides sufficient liquidity for at least 12 months.
- Nasdaq Compliance: The Company received a delisting notice in June 2025 for failing to meet stockholders' equity and minimum bid price requirements. The reverse stock split and subsequent financing were executed to regain compliance. Nasdaq confirmed compliance with the bid price requirement in October 2025.
- Legal Contingency: Renovaro Inc. filed a lawsuit in May 2025 alleging breach of a Letter of Intent regarding a proposed merger. The Company contests the claim, but the outcome is uncertain and could materially impact financial condition.
- Risks: Significant risks include the volatility of ATH token prices, regulatory uncertainty regarding digital assets, potential classification as an investment company, and the operational risks of managing a cryptocurrency treasury.
Investor Verification Checklist
- Derivative Liability Valuation: Verify the assumptions used in the Monte Carlo simulation for the $74.4M derivative liability and confirm the settlement terms of the Crypto PIPE warrants.
- ATH Token Holdings: Confirm the current market value, custody arrangements, and liquidity status (locked vs. unlocked) of the 5.7 billion ATH tokens held.
- Renovaro Litigation: Monitor the status of the Delaware Chancery Court lawsuit filed by Renovaro and any potential settlement or judgment impacts.
- Nasdaq Status: Confirm continued compliance with Nasdaq listing requirements, specifically the $2.5 million stockholders' equity requirement, following the October 2025 financing.
- Going Concern: Assess whether the $50.8M cash raise and ATH holdings are sufficient to cover operating losses and lease obligations without further dilution.